Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.60 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13216478 | 0.75 | HSD11B1 (1.00) | HSD11B1ALDH1A1DPP4 | |
| SCHEMBL10844499 | 0.69 | HSD11B1 (0.45) | HSD11B1ALDH1A1SMN1; SMN2DPP4 | |
| SCHEMBL14953127 | 0.67 | HSD11B1 (0.37) | HSD11B1ALDH1A1SMN1; SMN2 | |
| SCHEMBL22811898 | 0.67 | HSD11B1 (0.51) | HSD11B1SCN9AALDH1A1SMN1; SMN2 | |
| SCHEMBL5679506 | 0.65 | HSD11B1 (0.42) | HSD11B1 | |
| SCHEMBL17008352 | 0.65 | ALDH1A1 (0.44) | HSD11B1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5353785 | 0.64 | HSD11B1 (0.41) | HSD11B1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3697996 | 0.64 | HSD11B1 (0.32) | HSD11B1ALDH1A1SMN1; SMN2 | |
| SCHEMBL16448628 | 0.64 | HSD11B1 (0.36) | HSD11B1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21075546 | 0.64 | HSD11B1 (0.41) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170002017-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| EP-2855428-A1 | N-SUBSTITUTED BENZAMIDES AND THEIR USE IN THE TREATMENT OF PAIN | Genentech, Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8952169-B2 | N-substituted benzamides and methods of use thereof | XENON PHARMACEUTICALS INC. (CA) | 2015-02-10 | — | — | US | disclosed |
| US-8952169-B2 | N-substituted benzamides and methods of use thereof | XENON PHARMACEUTICALS INC. (CA) | 2015-02-10 | — | — | US | disclosed |
| US-8952169-B2 | N-substituted benzamides and methods of use thereof | XENON PHARMACEUTICALS INC. (CA) | 2015-02-10 | — | — | US | disclosed |
| US-20130317001-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2013-11-28 | — | — | US | disclosed |
| WO-2013177224-A1 | N-SUBSTITUTED BENZAMIDES AND THEIR USE IN THE TREATMENT OF PAIN | GENENTECH, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002017-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SNRPD2 | HSD11B1 2602/4885SCN9A 1210/4885ALDH1A1 2216/4885 |
| US-20130317001-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SNRPD2 | HSD11B1 2602/4885SCN9A 1210/4885ALDH1A1 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.